Takeaway
- Current Medicare insulin pump policies present challenges to people with type 1 diabetes (T1D) that could lead to delays in receiving supplies and subsequent adverse outcomes.
Why this matters
- People with T1D are living longer, and more are becoming eligible for Medicare.
Study design
- Survey of 241 adults with T1D who had been on insulin pumps with Medicare coverage for ≥6 months.
- Funding: None.
Key results
- Reported problems included difficulties in obtaining supplies (56%), getting paperwork completed (24%), and getting the required face-to-face provider visits every 90 days (18%).
- Changed behaviors resulting from delayed access to supplies, reported by 39% overall, included leaving sites in place beyond the recommended 3 days (66%), reusing pump supplies (34%), using injections to compensate for inadequate supplies (23%), or temporarily stopping pump therapy (18%).
- Of 88 who had changed behaviors because of Medicare-related challenges, reported adverse effects included more erratic or higher blood glucose (48% and 42%, respectively), increased anxiety/frustration (44%), site pain/irritation (34%), and more site scarring (28%).
Limitations
- Respondents recruited from online community T1D Exchange Glu, predominantly well-educated, white, and well-managed patients.
- Those responding to the survey may have been more likely to have had negative experiences.
Only healthcare professionals with a Univadis account have access to this article.
You have reached your limit of complementary articles
Free Sign Up Available exclusively to healthcare professionals